Nobivac® Canine 1-DAPPv

NOBIVAC® CANINE 1-DAPPV

Dogs

Canine Class

>Vaccines – 1-year immunity

Nobivac® Canine 1-DAPPv



Biological name
Canine Distemper, Adenovirus Type 2, Parainfluenza, Parvovirus Vaccine, MODIFIED LIVE VIRUS


Proven 1-year vaccine that offers broad protection against canine parvovirus (CPV), adenovirus type 1 (hepatitis) and type 2 (respiratory disease), parainfluenza, and distemper.

Features and benefits

Protects against all known strains of CPV, including CPV-2c1–3

  • High antigenic mass (titer), low passage parvovirus vaccine
  • Canine vaccine containing CPV-2b, the most prevalent field strain of parvovirus
  • Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1 and 2, and parainfluenza in 1 formula
  • First to publish data showing protection against CPV-2c challenge1
  • Multiple studies demonstrate the ability to override maternal antibodies4

Indication

  • Approved for the vaccination of healthy dogs as an aid in the prevention of disease caused by canine distemper virus, adenovirus types 1 and 2, parainfluenza, and parvovirus
  • Recommended for use in healthy dogs 6 weeks of age or older

Safety information

Please see the product label for safety information.

Dosage and administration

  • Subcutaneous or intramuscular injection
  • Two 1-mL doses given 2 to 4 weeks apart
  • Primary vaccination may begin as early as 6 weeks. Last dose may be given at 12 weeks of age.
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS

References:

  1. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101.
  2. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.
  3. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1–2):48–55.
  4. Data on file, Merck Animal Health.
TRUSTe European Safe Harbor certification
Validate TRUSTe privacy certification